Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $2.37
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Mar 11, 26 |
Daily · Wilder smoothing
| Craig-Hallum |
| maintain |
| Buy |
| Buy |
| Mar 11, 26 | BTIG | upgrade | Neutral | Buy |
| Nov 12, 25 | Citizens | upgrade | Market Perform | Market Outperform |
| Nov 10, 23 | Stephens & Co. | maintain | Overweight | Overweight |
| Aug 11, 23 | Piper Sandler | maintain | Overweight | Overweight |
| Jun 15, 23 | Lake Street | maintain | Buy | Buy |
| May 24, 23 | JMP Securities | maintain | Market Perform | Perform |
| May 12, 23 | Lake Street | maintain | Buy | Buy |
| Aug 12, 22 | Piper Sandler | maintain | Overweight | Overweight |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 36.59 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 28.85 | Oscillator | Neutral |
| Williams %R (14) | -75.00 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.13 (Hist 0.01) | Oscillator | Buy |
| Average Directional Index (14) | 37.67 (+DI 10.6 / -DI 29.7) | Trend | Strong Sell |
| EMA 20 | 2.57 | MA | Strong Sell |
| SMA 20 | 2.52 | MA | Strong Sell |
| EMA 50 | 2.86 | MA | Strong Sell |
| SMA 50 | 2.82 | MA | Strong Sell |
| SMA 200 | 3.63 | MA | Strong Sell |
TTM vs. 5-year historical average (annual ratios)
| Metric | APYX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -11.5x | -10.6x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -8.9x | EPS est. -0.27 | Discount |
| Price / Book | 9.4x | 5.6x | Elevated |
| Price / Sales | 1.7x | 3.3x | Discount |
| EV / EBITDA | -69.7x | -15.0x | Elevated |
| Return on equity | -78.7% | — | Weak |
| Gross margin | 33.9% | 59.2% | Below hist. |
| Debt / Equity | 3.72 | 1.38 | Levered |
| Piotroski / Altman Z | 3/9 | Z 0.72 | Distress |
Discounted cash flow model
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jun 30, 26 | Waldman Lawrence | director | M-Exempt | 12,000 @ $1.88 | $22.56K |
| Jun 30, 26 | Waldman Lawrence | director | F-InKind | 5,024 @ $4.49 | $22.56K |
| Jun 30, 26 | Waldman Lawrence | director | M-Exempt | 12,000 @ $1.88 | $22.56K |
| Jun 15, 26 | Roman Shawn David | officer: Chief Operating Officer | F-InKind | 10,533 @ $4.60 | $48.45K |
| Jun 15, 26 | Roman Shawn David | officer: Chief Operating Officer | M-Exempt | 15,000 @ $3.23 | $48.45K |
| Jun 15, 26 | Roman Shawn David | officer: Chief Operating Officer | M-Exempt | 15,000 @ $3.23 | $48.45K |
| Jun 11, 26 | Levine Wendy Lauren | director | A-Award | 50,000 @ $4.65 | $232.5K |
| Jun 11, 26 | Vizirgianakis Stavros G. | director | A-Award | 450,000 | — |
| 8-K | Jul 24, 2026 | 2026-07-24 17:18:18 | View |
| SC 13G/A | Jul 21, 2026 | 2026-07-21 12:55:59 | View |
| 4 | Jul 2, 2026 | 2026-07-02 17:00:23 | View |
| DEF 14A | Jun 26, 2026 | 2026-06-26 16:13:49 | View |
| 4 | Jun 17, 2026 | 2026-06-17 17:15:02 | View |
| 8-K | Jun 17, 2026 | 2026-06-17 16:05:19 | View |
Proxy statement (DEF 14A) disclosures
Stock news · updated daily
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Apyx Medical Corporation (NASDAQ: APYX) on behalf of the company's shareholders. The investigation seeks to determine whether Apyx Medical Corporation's directors breached their fiduciary duties in connection with recent corporate actions.
CLEARWATER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the third quarter of fiscal year 2026 will be released before markets open on Thursday, November 5th.
CLEARWATER, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will present at the following investor conferences: UBS Global Healthcare Conference – November 9-11, 2026 (Miami, FL) Management will participate in a fireside chat at 10:15am ET and will host one-on-one meetings with investors on Monday, November 9.
CLEARWATER, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced results from a prospective clinical study evaluating the effects of Renuvion helium plasma radiofrequency technology on biological markers of skin quality.
Apyx Medical NASDAQ: APYX is positioning its Renuvion technology and newly launched AYON Body Contouring System to address growing demand for surgical aesthetic procedures, a trend CEO Charlie Goodwin said has been reshaped by the increasing use of GLP-1 weight-loss drugs.
Apyx Medical Corporation (NASDAQ: APYX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and one has given
Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript
Apyx Medical NASDAQ: APYX reported second-quarter revenue growth of 22% as sales in its surgical aesthetics business increased, led by adoption of its AYON Body Contouring System, international generator sales and domestic demand for single-use handpieces.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -0.08 | -0.07 | Beat 14.6% | $13.88M |
| May 7, 2026 | -0.11 | -0.05 | Beat 54.5% | $12.49M |
| Mar 10, 2026 | -0.06 | -0.03 | Beat 50.0% | $19.16M |
| Nov 6, 2025 | -0.06 | -0.05 | Beat 16.7% | $12.88M |
| Aug 7, 2025 | -0.09 | -0.09 | Beat 3.6% | $11.37M |
| May 8, 2025 | -0.12 | -0.10 | Beat 16.7% | $9.43M |